MetaVia Inc. (NASDAQ:MTVA) Short Interest Update

MetaVia Inc. (NASDAQ:MTVA) was the target of a large increase in short interest in the month of March. As of March 31st, there was short interest totaling 56,743 shares, an increase of 22.9% from the March 15th total of 46,186 shares. Based on an average daily volume of 181,127 shares, the days-to-cover ratio is presently 0.3 days. Currently, 1.1% of the company’s stock are short sold.

MetaVia Price Performance

Shares of NASDAQ MTVA remained flat at $1.40 during trading on Friday. 36,881 shares of the stock traded hands, compared to its average volume of 136,614. The company’s 50 day moving average price is $1.47 and its two-hundred day moving average price is $5.82. The firm has a market capitalization of $7.22 million, a P/E ratio of -0.17 and a beta of 0.35. MetaVia has a 12-month low of $1.17 and a 12-month high of $19.03.

Institutional Investors Weigh In On MetaVia

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC bought a new stake in MetaVia Inc. (NASDAQ:MTVA) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia as of its most recent SEC filing. Institutional investors own 1.37% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on MTVA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of MetaVia in a research report on Monday, December 22nd. Wall Street Zen upgraded MetaVia from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Finally, HC Wainwright decreased their price objective on MetaVia from $40.00 to $20.00 and set a “buy” rating for the company in a report on Friday, March 27th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, MetaVia has an average rating of “Hold” and an average price target of $26.50.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.